Abstract
Reversibility of hepatic fibrosis is an intrinsic response to chronic injury, and with on-going damage, fibrosis can progress to its end-stage consequence, cirrhosis. Non-invasive and reliable biomarkers for early detection of liver fibrosis are needed. Based on the CCl4-induced liver fibrosis rat model, urinary and serum metabolic profiling performed by LC-QTOF-MS associated with histological progression were utilized to identify liver fibrosis-specific potential biomarkers for early prediction and to reveal significant fibrotic pathways and their dynamic changes in different stages of liver fibrosis. Finally, nine differential metabolites in urine and ten in serum were selected and identified involving the most relevant metabolic pathways. Perturbations of tryptophan, valine, leucine, isoleucine, and citrate (TCA) cycle metabolites, along with sphingolipid and glycerophospholipid metabolites, occurred from the onset of liver fibrosis. Furthermore, dysregulation of valine and bile acid biosynthesis metabolites occurred in the intermediate and advanced stages. More importantly, among these metabolites, urinary kynurenic acid, 5-hydroxyindoleacetyl glycine, 4-(2-amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid and serum sphinganine, sphingomyelin, L-leucine, L-tryptophan, and LysoPC(17:0) changed at all time points and may serve as potential early biomarkers for the diagnosis of hepatic fibrosis and as therapeutic targets. Overall, this work evaluates the potential of these metabolites for the early detection of liver fibrosis.
Highlights
Hepatic fibrosis results from a dynamic process regarded as the result of extracellular matrix (ECM) accumulation following liver injury[1]
Evaluation of hepatic fibrosis is primarily based on a liver biopsy (LB), which is considered the golden standard for diagnosis
Identification of sensitive and specific biomarkers for the early detection of hepatic fibrosis is of great importance
Summary
Hepatic fibrosis results from a dynamic process regarded as the result of extracellular matrix (ECM) accumulation following liver injury[1]. Repeated injections of CCl4 cause liver damage, inflammation and fibrosis in rats that are clinically similar to the human pathology of liver fibrosis, as assessed by serum analysis and histological staining[19] To data, this model has been used for the elucidation of the mechanism of underlying the pathogenesis of liver fibrosis and diagnostic biomarker discovery[20,21,22]. This model has been used for the elucidation of the mechanism of underlying the pathogenesis of liver fibrosis and diagnostic biomarker discovery[20,21,22] These studies have limited value in identifying changes in biomarkers of hepatic fibrosis and for monitoring the entire development and disease progression process. Few of studies have investigated the combination of urine and serum metabolomics profiling, which can provide more comprehensive insights into the pathogenesis of liver fibrosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
